Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 12
Summary
- Conditions
- Melanoma (Skin)
- Skin Cancer
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02652455
- Collaborators
- Bristol-Myers Squibb
- Prometheus Inc.
- Iovance Biotherapeutics, Inc.
- Investigators
- Principal Investigator: Amod Sarnaik, M.D. H. Lee Moffitt Cancer Center and Research Institute
Get Well Soon